FierceBiotech November 25, 2025

<a href="https://www.fiercebiotech.com/biotech/bayers-asundexian-cuts-stroke-risk-phase-3-reviving-hopes-fxia-class" hreflang="en">Bayer's asundexian cuts stroke risk in phase 3, reviving hopes for FXIa class</a>

Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk of stroke in a phase 3 trial, giving a boost to a potentially blockbuster mechanism that has suffered setbacks over the past two years.